Cariprazine or Placebo for Depression Related to Bipolarity
About this title
Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression
Read the official source — NCT01396447Researchers compared Cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Understand this study
What did researchers investigate?
Researchers compared Cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 87 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 584
- Sponsor
- Forest Laboratories
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada, Bulgaria, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01396447
- Official title
Show the full official title
A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Birmingham, United States · Springdale, United States · Beverly Hills, United States
68 more locations
- Cerritos, United States
- Costa Mesa, United States
- Oceanside, United States
- Temecula, United States
- Jacksonville, United States
- Orlando, United States
- Winter Park, United States
- Atlanta, United States
- Chicago, United States
- Indianapolis, United States
- Prairie Village, United States
- Lake Charles, United States
- Shreveport, United States
- Flowood, United States
- Creve Coeur, United States
- Las Vegas, United States
- Cherry Hill, United States
- Marlton, United States
- Albuquerque, United States
- Brooklyn, United States
- New York, United States
- Canton, United States
- Dayton, United States
- Salem, United States
- Allentown, United States
- Media, United States
- Lincoln, United States
- Memphis, United States
- Dallas, United States
- Houston, United States
- San Antonio, United States
- Bellevue, United States
- Seattle, United States
- Kardzhali, Bulgaria
- Kazanlak, Bulgaria
- Lovech, Bulgaria
- Novi Iskar, Bulgaria
- Pazardzhik, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Tsarev Brod, Bulgaria
- Tserova Koria, Bulgaria
- Kelowna, Canada
- Penticton, Canada
- Chatham, Canada
- Barranquilla, Colombia
- Bogotá, Colombia
- Pereira, Colombia
- Arkhangelsk, Russia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Saratov, Russia
- Tomsk, Russia
- Tver', Russia
- Voronezh, Russia
- Kerch, Ukraine
- Kherson, Ukraine
- Donetsk, Ukraine
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kyiv, Ukraine
- Odesa, Ukraine
- Simferopol, Ukraine
- Vinnytsia, Ukraine
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Who is behind this study?
The study sponsor is Forest Laboratories, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Placebo and Cariprazine.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
